Symptomatic effect of a long acting Lanreotide formulation in patients with gastrointestinal neuroendocrine tumours.

被引：0
|
作者：
Jacobsen, MB [1 ]
deVries, EGE [1 ]
Eriksson, B [1 ]
Fiasse, R [1 ]
Wijmenga, M [1 ]
Salmela, P [1 ]
Valimaki, M [1 ]
Oberg, K [1 ]
Renstrup, J [1 ]
机构：
[1] UNIV OSLO, OSLO, NORWAY
来源：
GASTROENTEROLOGY | 1996年 / 110卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：A535 / A535
页数：1
相关论文
共 50 条
  • [1] Gastrointestinal neuroendocrine tumours. Prospective analysis of 29 patients and literature review
    Wenisch, HJC
    ZENTRALBLATT FUR CHIRURGIE, 2001, 126 (01): : 23 - 31
  • [2] Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors
    Ricci, S
    Antonuzzo, A
    Galli, L
    Orlandini, C
    Ferdeghini, M
    Boni, G
    Roncella, M
    Mosca, F
    Conte, PF
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2000, 23 (04): : 412 - 415
  • [3] The antitumoral effect of the long-acting somatostatin analog lanreotide in neuroendocrine tumors
    Ducreux, M
    Ruszniewski, P
    Chayvialle, JA
    Blumberg, J
    Cloarec, D
    Michel, H
    Raymond, JM
    Dupas, JL
    Gouerou, H
    Jian, R
    Genestin, E
    Hammel, P
    Rougier, P
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2000, 95 (11): : 3276 - 3281
  • [4] Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors
    Ayyagari, Rajeev
    Neary, Maureen
    Li, Shang
    Rokito, Ariel
    Yang, Hongbo
    Xie, Jipan
    Benson, Al B., III
    AMERICAN HEALTH AND DRUG BENEFITS, 2017, 10 (08): : 408 - 415
  • [5] Long-acting lanreotide in the treatment of neuroendocrine tumors (NETs)
    Antonuzzo, A
    Ricci, S
    Galli, L
    Conte, PF
    ANNALS OF ONCOLOGY, 1998, 9 : 175 - 175
  • [6] Long-acting release lanreotide in the treatment of neuroendocrine tumors
    Ruszniewski, P
    ANNALES D ENDOCRINOLOGIE, 1998, 59 : 51 - 52
  • [7] Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly
    Caron, P
    Beckers, A
    Cullen, DR
    Goth, MI
    Gutt, B
    Laurberg, P
    Pico, AM
    Valimaki, M
    Zgliczynski, W
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (01): : 99 - 104
  • [8] Response to Treatment and Quality of Life in Patients with Symptomatic Gastroenteropancreatic Neuroendocrine Tumours Treated with Lanreotide Autogel in South Africa
    Szpak, W.
    Geldenhuys, D.
    Rapoport, B. L.
    Nel, M.
    Madzivhandila, M.
    Mothilal, R.
    McMaster, A.
    NEUROENDOCRINOLOGY, 2019, 108 : 164 - 164
  • [9] Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly
    G. Lombardi
    F. Minuto
    G. Tamburrano
    M. R. Ambrosio
    G. Arnaldi
    M. Arosio
    V. Chiarini
    R. Cozzi
    S. Grottoli
    F. Mantero
    F. Bogazzi
    M. Terzolo
    P. Tita
    P. F. Boscani
    A. Colao
    Journal of Endocrinological Investigation, 2009, 32 : 202 - 209
  • [10] Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly
    Lombardi, G.
    Minuto, F.
    Tamburrano, G.
    Ambrosio, M. R.
    Arnaldi, G.
    Arosio, M.
    Chiarini, V.
    Cozzi, R.
    Grottoli, S.
    Mantero, F.
    Bogazzi, F.
    Terzolo, M.
    Tita, P.
    Boscani, P. F.
    Colao, A.
    JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2009, 32 (03): : 202 - 209
12345